Merck Says Keytruda/Chemo Combination Improves Overall Survival Compared to…
Merck & Co Inc MRK announced results from the pivotal Phase 3 KEYNOTE-859 study of Keytruda (pembrolizumab) with fluoropyrimidine and platinum-based chemotherapy for gastric cancer.